Patents by Inventor Xiaohong He
Xiaohong He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148894Abstract: Provided is use of an antibody-drug conjugate targeting Her2 in the preparation of a medicine for treating breast cancer patients with liver metastasis or breast cancer patients without lung metastasis. Compared with a control drug group (lapatinib+capecitabine), the application of the antibody-drug conjugate provided in the treatment of breast cancer patients with liver metastasis and in the treatment of breast cancer patients without lung metastasis can significantly improve the survival time of the patients.Type: ApplicationFiled: August 16, 2023Publication date: May 9, 2024Inventors: Jianmin FANG, Xiaohong SU, Xuguang GUO, Ruyi HE
-
Publication number: 20240082306Abstract: Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a ?C chain or intracellular region thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.Type: ApplicationFiled: December 7, 2021Publication date: March 14, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Gong CHEN, Tingting GUO, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20240052029Abstract: Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.Type: ApplicationFiled: January 12, 2022Publication date: February 15, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Gong CHEN, Tingting GUO, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN, Guokun LI, Jing ZHANG, Huifang SUN
-
Patent number: 11896620Abstract: An engineered immune cell, which expresses (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and/or XCL1; the engineered immune cell can be used for treating cancer, infection, or autoimmune diseases; and compared with a traditional engineered immune cell, the engineered immune cell has significantly improved tumor killing activity.Type: GrantFiled: May 24, 2021Date of Patent: February 13, 2024Assignee: BIOHENG THERAPEUTICS LIMITEDInventors: Yun Xing, Zhonghui Yan, Ying Xiong, Rongrong Pu, Jiangtao Ren, Xiaohong He, Yanbin Wang, Lu Han
-
Publication number: 20240043532Abstract: Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with NKG2A expression.Type: ApplicationFiled: November 18, 2021Publication date: February 8, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Tingting GUO, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20240018251Abstract: Provided in the present invention are a BCMA-targeting single-domain antibody and an encoding nucleotide sequence thereof. Also provided in the present invention are a multispecific antibody, a chimeric antigen receptor, and an antibody conjugate containing the BCMA single domain antibody, and a pharmaceutical composition and kit containing said antibodies, chimeric antigen receptor and antibody conjugate, and the use thereof in the diagnosis/treatment/prevention of diseases associated with BCMA expression.Type: ApplicationFiled: October 25, 2021Publication date: January 18, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Guokun LI, Rongrong PU, Jiangtao REN, Xiaohong He, Yanbin Wang, Lu HAN
-
Publication number: 20240018236Abstract: The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.Type: ApplicationFiled: December 7, 2021Publication date: January 18, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Xiaoyan JIANG, Gong CHEN, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20240009308Abstract: Provided is a chimeric antigen receptor, comprising a ligand-binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. The co-stimulatory domain comprises an intracellular region of an NK-activated receptor or a ligand thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a use thereof in treatment of diseases, such as cancers, autoimmune diseases, and infections.Type: ApplicationFiled: September 9, 2021Publication date: January 11, 2024Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20240009311Abstract: Provided is an engineered immune cell. The engineered immune cell expresses (i) a chimeric receptor, and (ii) exogenous CCL3, CCL4 and/or CCL5, has improved tumor killing activity, and can be used to treat cancer, infection or autoimmune diseases.Type: ApplicationFiled: August 12, 2021Publication date: January 11, 2024Inventors: Yun XING, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230399398Abstract: The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.Type: ApplicationFiled: October 29, 2021Publication date: December 14, 2023Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Xiaoyan JIANG, Gong CHEN, Jiangtao REN, Xiaohong He, Yanbin Wang, Lu HAN
-
Publication number: 20230390336Abstract: Provided is an engineered immune cell. The cell expresses a chimeric antigen receptor comprising an antigen-binding region. The antigen-binding region comprises an anti-CD7 antibody, and the expression of endogenous CD7, at least one TCR/CD3 gene, and at least one MHC-II related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of diseases associated with CD7 expression.Type: ApplicationFiled: October 29, 2021Publication date: December 7, 2023Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Xiaoyan JIANG, Gong CHEN, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Patent number: 11766704Abstract: A sea creature cleaning robot for an intake tunnel for a nuclear power plant includes a frame, cutter assemblies, and walking wheel assemblies; the frame is used for mounting and fixing cutter mounting seats and crawler wheels; the walking wheel assemblies mounted on the frame enable the entire device to normally walk in a tunnel; the cutter assemblies control the height of cutters by means of hydraulic cylinders to make the cutters contact the inner wall of the tunnel, and the hydraulic cylinders drive the saw-toothed cutters to move back and forth to remove sea creatures attached to the inner wall of the tunnel; the cutter assemblies are uniformly distributed on the frame, so as to ensure full coverage of the cleaning range of the cross section of the tunnel. The robot can clean sea creatures in tunnels in place of manual work to significantly improve the cleaning efficiency.Type: GrantFiled: April 4, 2020Date of Patent: September 26, 2023Assignee: CHENGDU UNIVERSITY OF INFORMATION TECHNOLOGYInventors: Gexiang Zhang, Qiang Yang, Ming Zhu, Qiyu Liu, Qiang Yang, Xiaohong He, Minyao Tan, Li Yang, Jun Liu, Zhenyu Wang, Dapeng Zhang, Jiawei Wang, Xiang Chen, Xiaozhao Jin
-
Publication number: 20230270858Abstract: A chimeric antigen receptor, containing a ligand binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain, the co-stimulatory domain containing CD94 and/or LT? intracellular regions. The present invention further relates to engineered immune cells containing such a chimeric antigen receptor, and uses thereof in the treatment of diseases, such as cancer, autoimmune diseases, and infections.Type: ApplicationFiled: August 19, 2021Publication date: August 31, 2023Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230248768Abstract: Provided is an engineered immune cell. The expressions of at least one MHC related gene and at least one NK activating receptor binding molecule are suppressed or silenced, so as to suppress the killing of the engineered immune cell by NK cells. Also provided are a pharmaceutical composition comprising the engineered immune cell and use of the engineered immune cell in preparation of drugs for treatment of cancer, infection, or autoimmune diseases.Type: ApplicationFiled: July 14, 2021Publication date: August 10, 2023Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230242877Abstract: The invention relates to an engineered immune cell comprising: (a) a first nucleic acid sequence encoding a chimeric antigen receptor or a chimeric antigen receptor encoded thereby, said chimeric antigen receptor comprises a first antigen binding region, a transmembrane domain, and an intracellular signaling domain; and (b) a second nucleic acid sequence encoding an Fc fusion polypeptide or an Fc fusion polypeptide encoded thereby, said Fc fusion polypeptide comprises a second antigen binding region and an Fc region, wherein the first antigen binding region and the second antigen binding region are not scFv at the same time. The invention also relates to compositions comprising the engineered immune cells of the invention, and the use of the engineered immune cells/compositions in the treatment of cancer.Type: ApplicationFiled: January 21, 2021Publication date: August 3, 2023Inventors: Qiping SHI, Wen JIANG, Xiaohong HE, Jiangtao REN, Yanbin WANG, Lu HAN
-
Publication number: 20230242661Abstract: Provided is an NK inhibitory molecule, which includes one or more NK inhibitory ligands, a transmembrane domain and a co-stimulatory domain, wherein the NK inhibitory ligand specifically binds to NK inhibitory receptors to inhibit the killing of NK cells against the engineered immune cells expressing the NK inhibitory molecule. Also provided is an engineered immune cell expressing the NK inhibitory molecule of the present invention, wherein the expression of at least one MHC-related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of cancers, infections or autoimmune diseases. Compared to the traditional engineered immune cells, the engineered immune cell can significantly inhibit the killing effect of NK cells in a subject, thereby reducing the risk of HvGD.Type: ApplicationFiled: June 10, 2021Publication date: August 3, 2023Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230138756Abstract: An engineered immune cell, which expresses (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and/or XCL1; the engineered immune cell can be used for treating cancer, infection, or autoimmune diseases; and compared with a traditional engineered immune cell, the engineered immune cell has significantly improved tumor killing activity.Type: ApplicationFiled: May 24, 2021Publication date: May 4, 2023Inventors: Yun XING, Zhonghui YAN, Ying XIONG, Rongrong PU, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230122479Abstract: A sea creature cleaning robot for an intake tunnel for a nuclear power plant includes a frame, cutter assemblies, and walking wheel assemblies; the frame is used for mounting and fixing cutter mounting seats and crawler wheels; the walking wheel assemblies mounted on the frame enable the entire device to normally walk in a tunnel; the cutter assemblies control the height of cutters by means of hydraulic cylinders to make the cutters contact the inner wall of the tunnel, and the hydraulic cylinders drive the saw-toothed cutters to move back and forth to remove sea creatures attached to the inner wall of the tunnel; the cutter assemblies are uniformly distributed on the frame, so as to ensure full coverage of the cleaning range of the cross section of the tunnel. The robot can clean sea creatures in tunnels in place of manual work to significantly improve the cleaning efficiency.Type: ApplicationFiled: April 4, 2020Publication date: April 20, 2023Applicant: CHENGDU UNIVERSITY OF INFORMATION TECHNOLOGYInventors: Gexiang ZHANG, Qiang YANG, Ming ZHU, Qiyu LIU, Qiang YANG, Xiaohong HE, Minyao TAN, Li YANG, Jun LIU, Zhenyu WANG, Dapeng ZHANG, Jiawei WANG, Xiang CHEN, Xiaozhao JIN
-
Publication number: 20200377878Abstract: The present invention relates to modified T cells with reduced or abolished TCR/CD3 complex expression, and the methods to produce the same. Also included are pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as cancer, infections or autoimmune diseases.Type: ApplicationFiled: August 11, 2020Publication date: December 3, 2020Inventors: Yali ZHOU, Jiangtao REN, Xiaohong HE
-
Patent number: D964772Type: GrantFiled: February 22, 2022Date of Patent: September 27, 2022Assignee: TONGXIANG GUIZHENG TRADE CO., LTD.Inventor: Xiaohong He